These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 4951928)

  • 1. Hemophilia prophylaxis with factor VIII concentrate.
    Kasper CK; Dietrich SL; Rapaport SI
    Arch Intern Med; 1970 Jun; 125(6):1004-9. PubMed ID: 4951928
    [No Abstract]   [Full Text] [Related]  

  • 2. Calculating the dose of factor VIII in the management of haemophilia.
    Ingram GI
    Br J Haematol; 1981 Jun; 48(2):351-4. PubMed ID: 6786322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Letter: Treatment of inhibitors to factor VIII with activated prothrombin concentrate.
    Sultan Y; Brouet JC; Debre P
    N Engl J Med; 1974 Nov; 291(20):1087. PubMed ID: 4414451
    [No Abstract]   [Full Text] [Related]  

  • 4. [Treatment of hemophilia A with actor VIII concentrate in urological operations and injuries of the urinary tract].
    Brühl P; Weibbach L; Brackmann HH
    MMW Munch Med Wochenschr; 1975 Mar; 117(10):401-4. PubMed ID: 804604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hemostatic management in hemophilia A. Usefulness of APTT and TEG as a method for monitoring Factor VIII concentrates].
    Watanabe S; Ito S; Igarashi S; Itamoto M; Harada N; Kanazawa M; Sato M; Yasukouji T
    Shoni Shikagaku Zasshi; 1985; 23(3):760-8. PubMed ID: 3938858
    [No Abstract]   [Full Text] [Related]  

  • 6. [Outcome of hemorrhage treatment in children with hemophilia A related to factor VIII inhibitor].
    Klukowska A; Zieleniewska B
    Acta Haematol Pol; 1994; 25(4):349-54. PubMed ID: 7847036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor VIII half-life and clinical phenotype of severe hemophilia A.
    van Dijk K; van der Bom JG; Lenting PJ; de Groot PG; Mauser-Bunschoten EP; Roosendaal G; Grobbee DE; van den Berg HM
    Haematologica; 2005 Apr; 90(4):494-8. PubMed ID: 15820945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and indications for continuous infusion of antihemophilic factor (factor VIII).
    Goldsmith JC
    Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S3-6. PubMed ID: 8735789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The problem of factor VIII inhibitors in patients with congenital coagulopathies].
    Klare M
    Z Gesamte Inn Med; 1983 Jan; 38(2):47-50. PubMed ID: 6407220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of a single administration of cryoprotein and plasma on factor VIII in hemophilia A].
    Vlcková M; Vorlová Z
    Vnitr Lek; 1980 Nov; 26(11):1101-6. PubMed ID: 6789551
    [No Abstract]   [Full Text] [Related]  

  • 11. Delivery of treatment for haemophilia.
    Haemophilia; 2003 Jul; 9(4):403-4. PubMed ID: 12828676
    [No Abstract]   [Full Text] [Related]  

  • 12. [Suppression of an anti-factor VIII inhibitor using the simultaneous administration of prednisone and factor VIII].
    Díaz Cremades JM
    Sangre (Barc); 1985; 30(1):59-60. PubMed ID: 3923634
    [No Abstract]   [Full Text] [Related]  

  • 13. Experience gained in 35 operations in patients with hemophilia A.
    Ziemski JM; Lopaciuk S; Rudowski W
    Pol Med J; 1971; 10(5):1269-77. PubMed ID: 5133676
    [No Abstract]   [Full Text] [Related]  

  • 14. Factor VIII half-life and intensity of treatment in hemophilic patients.
    Vicente V
    Haematologica; 2005 Apr; 90(4):437. PubMed ID: 15820932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Use of a basic study profile for diagnostic certainty in hemophilia A].
    Ambriz-Fernández R; Avilés-Miranda A; Reyna-Fregoso MP; Ballesteros-Téllez L; Pizzuto-Chávez J
    Gac Med Mex; 1983 Dec; 119(12):477-82. PubMed ID: 6421644
    [No Abstract]   [Full Text] [Related]  

  • 16. Kinetic analysis of bovine factor VIII in the hemophilic dog.
    Gentry PA; Kirby EP; Gentry RD
    Thromb Haemost; 1981 Aug; 46(2):485-8. PubMed ID: 6795739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma fractions for the treatment of hemophilia. 1. On the preparation and use of fraction I-O.
    Blombäck M; Blombäck B
    Thromb Diath Haemorrh Suppl; 1969; 35():21-5. PubMed ID: 5317539
    [No Abstract]   [Full Text] [Related]  

  • 18. Transient factor VIII inhibitor in a hemophilia patient after staphylococcal septic shock syndrome.
    Yamamoto K; Niiya K; Shigematu T; Kiguchi T; Takenaka K; Shinagawa K; Ishimaru F; Ikeda K; Shima M; Harada M
    Int J Hematol; 2000 Dec; 72(4):517-9. PubMed ID: 11197224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylaxis and continuous infusion for hemophilia: can we afford it?
    Aledort LM; Bohn RL
    Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S35-7. PubMed ID: 8735795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal purified F VIII for continuous infusion: stability, microbiological safety and clinical experience.
    Schulman S; Varon D; Keller N; Gitel S; Martinowitz U
    Thromb Haemost; 1994 Sep; 72(3):403-7. PubMed ID: 7855792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.